Cinarizine - instructions for use, dose, side effects, contraindications

1 tablet contains as active substance 25 mg of cinnarizine and excipients: aerosil, calcium stearate, potato starch, lactose (milk sugar), polyvinylpyrrolidone (povidone), low molecular weight medical.

Description:

Tablets are white or white with a creamy shade of color, flat-cylindrical with a bevel.

Pharmacotherapeutic group:The blocker of "slow" calcium channels.

ATX: & nbsp

N.07.C.A.02 Cinnarizine

Pharmacodynamics:

Cinnarizine - a selective blocker of "slow" calcium channels, reduces the entry of calcium ions into cells and reduces their concentration in the depot of plasmolemmas, reduces the tone of the smooth muscles of arterioles, strengthens the vasodilating effect of carbon dioxide. Directly affecting the smooth muscles of blood vessels, reduces their response to biogenic vasoconstrictor substances (adrenaline and norepinephrine). It has a vasodilating effect (especially with respect to cerebral vessels), without having a significant effect on blood pressure. It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Effective in patients with latent insufficiency of cerebral circulation, initial atherosclerosis of cerebral vessels and chronic diseases of cerebral vessels with postinsultaneous focal symptoms. In patients with impaired peripheral circulation improves blood supply to organs and tissues (including myocardium), enhances postischemic vasodilation. Increases the elasticity of erythrocyte membranes, their ability to deform, reduces the viscosity of the blood.Increases muscle resistance to hypoxia.

Pharmacokinetics:

The maximum concentration in the blood plasma is achieved after oral administration in 1-3 hours. The connection with plasma proteins is about 91%. Completely metabolized in the liver by dealkylation. The half-life is 4 hours. It is excreted in the form of metabolites: 1/3 - kidney, 2/3 - intestine.

Indications:

The period of convalescence after a previous ischemic and hemorrhagic stroke, craniocerebral trauma; encephalopathy; labyrinthine disorders (including for maintenance therapy for dizziness, tinnitus, nystagmus, nausea, vomiting of a labyrinthine origin); migraine, (prevention of seizures); Meniere's disease; sea and air sickness (prevention); violation of peripheral circulation (prevention and treatment) - obliterating endarteritis, obliterating thromboangiitis, Raynaud's disease, diabetic angiopathy, thrombophlebitis, trophic disorders, trophic and varicose ulcers, pregangrenous conditions, paresthesia, night spasms and cold extremities.

Contraindications:

Hypersensitivity to the drug, pregnancy, lactation, children under 12 years.

Carefully:

Parkinson's disease.

Dosing and Administration:

Inside, after eating.For violations of cerebral circulation - 25-50 mg 3 times a day; with violations of peripheral circulation - 50-75 mg 3 times a day; with labyrinthine disorders - 25 mg 3 times a day; with sea and air sickness, before the forthcoming trip; adults - 25 mg, if necessary, the dose is repeated after 6 hours. Children are prescribed half the dose for adults. The maximum daily dose should not exceed 225 mg.

With high sensitivity to the drug, treatment starts with ½ dose, increasing it gradually. The course of treatment is from several weeks to several months.

Side effects:

From the nervous system: drowsiness, increasedwfatigue, headache, extrapyramidal disorders (tremor of limbs and increased muscle tone, hypokinesia), depression.

From the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice.

On the part of the skin: increased sweating, red flat lichen (extremely rare).

Allergic reactions: skin rash.

Other: decreased blood pressure, increased body weight, development of lupus-like syndrome.

Overdose:

Symptoms: vomiting, drowsiness, tremor, excessive lowering of blood pressure, coma.

In case of overdose there is no specific antidote, it is necessary to do a gastric lavage and take Activated carbon.

Treatment - symptomatic.

Interaction:

Pharmaceutical: Chemical incompatibility is not known.

Pharmacodynamic: Strengthens the effect of alcohol, sedatives and antidepressant drugs. At simultaneous application with nootropic, antihypertensive and vasodilating agents strengthens their effect, and with simultaneous application with drugs prescribed for arterial hypotension - reduces their effect.

Pharmacokinetic: no data.

Special instructions:

At the beginning of treatment, ethanol intake should be avoided.

In connection with the presence of antihistamine effect cinnarizine can affect the result in the case of anti-doping control of athletes (false positive result), and also neutralize positive reactions in conducting skin diagnostic tests (for 4 days before the study treatment should be canceled).

With prolonged use, it is recommended that a control examination of the liver, kidneys,pictures of peripheral blood.

Women receiving cinnarizine, breast-feeding is not recommended.

Patients with Parkinson's disease should be prescribed only in cases where the benefits from its administration exceed the possible risk of deterioration.

Effect on the ability to drive transp. cf. and fur:

During the treatment period, care must be taken when driving vehicles and engaging in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

Form release / dosage:

Tablets 25 mg.

Packaging:

10 tablets in a planar cell package.

50 tablets in cans of orange glass.

5 contour mesh packages or a jar along with instructions for use are placed in a pack of cardboard.

Storage conditions:

In a dry, dark place at a temperature of 18 to 20 ° C. Keep out of the reach of children.

Shelf life:2 years. Do not use after the expiry date printed on the package

Terms of leave from pharmacies:On prescription

Registration number:LSR-002850/09

Date of registration:09.04.2009

The owner of the registration certificate:IRBITSK HFZ, OJSC IRBITSK HFZ, OJSC Russia

Manufacturer: & nbsp

IRBITSK HFZ, OJSC Russia

Information update date: & nbsp09.10.2015

Illustrated instructions

Instructions

Cinnarizine (Cinnarizine)